Pulmonary Edema Market Research Report- Forecast to 2027

Pulmonary Edema Market Research Report Information: By Type (Cardiogenic Edema), Diagnosis (Blood Tests, Imaging), Treatment (Morphine, Suction Catheter), End Users (Hospitals & Clinics, Academic Institutes, Retail Pharmacies) - Forecast Till 2027

ID: MRFR/Pharma/4158-HCR | February 2021 | Region: Global | 90 pages

Pulmonary Edema Market Scenario:


Pulmonary edema or lung congestion is a medical condition characterized by the presence of excessive fluid in the lungs. This may interfere with the exchange of gases leading to respiratory failures. Many cardiac and non-cardiac conditions are associated with the disease which occurs when the heart is unable to meet the body demands. This can be exampled by congestive heart failure. Dyspnea, palpitations, fatigue, wheezing, and others are some of the common symptoms of pulmonary edema. The treatment procedures for the disease vary with cause. However, supplemental oxygen and medications mount the backgrounds for a majority of the treatment methods. Increasing prevalence of pulmonary edema and diseases like kidney failure, heart diseases, pancreatitis is estimated to be the major driver for the pulmonary edema market growth during the forecast period. According to the National Kidney Foundation in 2015, about 10% of the world’s total population is estimated to be affected by chronic kidney diseases (CKD). Moreover, it is estimated that millions of patients diagnosed with the disease die every year due to unaffordability for treatment. Additionally, growing geriatric population boosts the pulmonary edema market growth. However, low per capita healthcare expenditure in the middle and low-income countries followed by the lack of awareness is projected to restrain the pulmonary edema market growth.


The pulmonary edema market is expected to grow at a CAGR of ~7.2% during the forecast period.


Intended Audience



  • Pharmaceutical companies

  • Biotechnological institutes

  • Research and Development (R&D) Companies

  • Medical Research Laboratories

  • Market Research and Consulting Service Providers


Figure 1:- Global Global Pulmonary Edema Market Share, by Region


 Pulmonary Edema


Sources: WHO, Annual Reports, Press Release, White Paper, and Company Presentation


Segmentation


The pulmonary edema market is segmented on the basis of type, diagnosis, treatment, and end user.


On the basis of the type, the pulmonary edema market is segmented into cardiogenic edema, cardiogenic edema, and others.


On the basis of the diagnosis, the pulmonary edema market is categorized into blood tests, imaging, and others. The blood tests segment is sub-segmented into b-type natriuretic peptide (BNP), blood count test, kidney function test, and others. The imaging segment is sub-segmented into chest x-ray, electrocardiogram, echocardiogram, transesophageal echocardiography, pulse oximetry, and others. On the basis of the treatment, the pulmonary edema market is segmented into preload reducers, morphine, suction catheter, and others. The preload reducers segment is sub-segmented into nitroglycerin, diuretics, and others. On the basis of the end users, the pulmonary edema marketis segmented into hospitals & clinics, academic institutes, retail pharmacies, and others.


Regional Analysis


America dominates the pulmonary edema market owing to a well-developed healthcare sector and high per capita healthcare expenditure. Moreover, the presence of developed economies like U.S. and Canada and global players such as Pfizer Inc., Edwards Lifesciences Corporation, ARGON MEDICAL, and others within the regional boundaries of the Americas fuels the pulmonary edema market growth.


Europe is the second largest pulmonary edema market and is followed by the Asia Pacific due to the availability of funds for research, the presence of developed economies like France, Italy, and Germany within the region. Additionally, growing geriatric population in Europe further boosts the pulmonary edema market growth. 


The Asia Pacific is the fastest growing region in the market due to the presence of developing economies like India and China within the region. Moreover, rising healthcare expenditure and favorable government policies drive the market growth. According to the Indian Brand Equity Foundation in 2018, Indian healthcare is the largest sector in terms of revenue & employment. Moreover, the industry is expected to grow at an exponential rate owing to increasing expenditure by the public and private players.


The Middle East & Africa holds the least share of the pulmonary edema market.  Presence of poor economies, especially within in the African region makes the market to lag. Middle East accounts for the majority of the market share in the Middle East & Africa region due to a huge healthcare expenditure by the presence of the developed economies such as Saudi Arabia, Kuwait, and Qatar within the region.


Research Methodology


 Research Methodology 1


Sources: WHO, annual reports, press release, white paper, and company presentation


Some of the key players in the Pulmonary Edema Market


Pfizer Inc. (U.S.), ARGON MEDICAL (U.S.), Edwards Lifesciences Corporation (U.S.), BD (U.S.), Alcaliber S.A. (Spain), Lupin Pharmaceuticals, Inc. (India), Vitaltec Corporation (China), Medtronic (U.S.), Koninklijke Philips N.V. (The Netherlands), Siemens Healthcare GmbH (Germany), Hitachi Medical Corporation (U.S.), and Canon Medical Systems Corporation (Japan).



Report Scope:
Report Attribute/Metric Details
  Market Size   2027: Significant Value
  CAGR   7.2% (2017-2023)
  Base Year   2019
  Forecast Period   2020-2027
  Historical Data   2018
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   Type, Diagnosis, Treatment, and End user
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Pfizer Inc. (U.S.), ARGON MEDICAL (U.S.), Edwards Lifesciences Corporation (U.S.), BD (U.S.), Alcaliber S.A. (Spain), Lupin Pharmaceuticals, Inc. (India), Vitaltec Corporation (China), Medtronic (U.S.), Koninklijke Philips N.V. (The Netherlands), Siemens Healthcare GmbH (Germany), Hitachi Medical Corporation (U.S.), and Canon Medical Systems Corporation (Japan)
  Key Market Opportunities   New product launches and R&D Amongst major key Players
  Key Market Drivers   Increasing prevalence of pulmonary edema and diseases


Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :


Pulmonary Edema Market is a condition wherein excessive fluid gathers in the lungs, making respiration difficult.

The market is expected to exhibit a strong 7.2% CAGR over the forecast period till 2023.

The growing prevalence of cardiovascular conditions is the major driver for the pulmonary edema market.

Americas dominates the global pulmonary edema market, followed by Europe.

Leading players in the pulmonary edema market include Edwards, Argon Medical, and Pfizer, among others.

TABLE OF CONTENT

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope of the Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power of Suppliers

5.1.2 Bargaining Power of Buyers

5.1.3 Threat of New Entrants

5.1.4 Threat of Substitutes

5.1.5 Intensity of Rivalry

5.2 Value Chain Analysis

5.3 Investment Feasibility Analysis

5.4 Pricing Analysis

Chapter 6. Global Pulmonary Edema Market, by Type

6.1 Introduction

6.2 Cardogenic Edema

Market Estimates & Forecast, 2020 – 2027

6.3 Cardogenic Edema

Market Estimates & Forecast, 2020 – 2027

6.4 Others

Chapter 7. Global Pulmonary Edema Market, by Diagnosis

7.1 Introduction

7.2 Blood Tests

Market Estimates & Forecast, 2020 – 2027

7.2.1 B-Type Natriuretic Peptide (BNP)

7.2.2 Blood Count Test

7.2.3 Kidney Function Test

7.2.4 Others

7.3 Imaging

Market Estimates & Forecast, 2020 – 2027

7.3.1 Chest X-ray

7.3.2 Electrocardiogram

7.3.3 Echocardiogram

7.3.4 Transesophageal Echocardiography

7.3.5 Pulse oximetry

7.3.6 Others

7.4 Others

Chapter 8. Global Pulmonary Edema Market, by Treatment

8.1 Introduction

8.2 Preload Reducers

Market Estimates & Forecast, 2020 – 2027

8.2.1 Nitroglycerin

8.2.2 Diuretics

8.2.3 Others

8.3 Morphine

Market Estimates & Forecast, 2020 – 2027

8.4 Suction Catheter

Market Estimates & Forecast, 2020 – 2027

8.5 Others

Chapter 9. Global Pulmonary Edema Market, by End User

9.1 Introduction

9.2 Hospitals & Clinics

Market Estimates & Forecast, 2020 – 2027

9.3 Academic Institutes

Market Estimates & Forecast, 2020 – 2027

9.4 Retail Pharmacies

Market Estimates & Forecast, 2020 – 2027

9.5 Others

Chapter 10. Global Pulmonary Edema Market, by Region

10.1 Introduction

10.2 America

10.2.1 North America

10.2.1.1 U.S.

10.2.1.2 Canada

10.2.2 South America

10.3 Europe

10.3.1 Western Europe

10.3.1.1 Germany

10.3.1.2 France

10.3.1.3 Italy

10.3.1.4 Spain

10.3.1.5 U.K

10.3.1.6 Rest of Western Europe

10.3.2 Eastern Europe

10.4 Asia Pacific

10.4.1 Japan

10.4.2 China

10.4.3 India

10.4.4 Australia

10.4.5 Republic of Korea

10.4.6 Rest of Asia Pacific

10.5 The Middle East & Africa

10.5.1 United Arab Emirates

10.5.2 Saudi Arabia

10.5.3 Oman

10.5.4 Kuwait

10.5.5 Qatar

10.5.6 Rest of the Middle East & Africa

Chapter 11. Company Landscape

11.1 Introduction

11.2 Market Share Analysis

11.3 Key Development & Strategies

11.3.1 Key Developments

Chapter 12 Company Profiles

12.1 Pfizer Inc.

12.1.1 Company Overview

12.1.2 Type Overview

12.1.3 Financials

12.2.4 Key Developments

12.1.5 SWOT Analysis

12.2 ARGON MEDICAL

12.2.1 Company Overview

12.2.2 Type Overview

12.2.3 Financial Overview

12.2.4 Key Developments

12.2.5 SWOT Analysis

12.3 Edwards Lifesciences Corporation

12.3.1 Company Overview

12.3.2 Type Overview

12.3.3 Financial Overview

12.3.4 Key Development

12.3.5 SWOT Analysis

12.4 BD

12.4.1 Company Overview

12.4.2 Type/Business Segment Overview

12.4.3 Financial Overview

12.4.4 Key Development

12.4.5 SWOT Analysis

12.5 Alcaliber S.A.

12.5.1 Company Overview

12.5.2 Type Overview

12.5.3 Financial overview

12.5.4 Key Developments

12.5.5 SWOT Analysis

12.6 Lupin Pharmaceuticals, Inc.

12.6.1 Company Overview

12.6.2 Type Overview

12.6.3 Financial Overview

12.6.4 Key Developments

12.6.5 SWOT Analysis

12.7 Vitaltec Corporation

12.7.1 Overview

12.7.2 Type Overview

12.7.3 Financials

12.7.4 Key Developments

12.7.5 SWOT Analysis

12.8 Medtronic

12.8.1 Overview

12.8.2 Type Overview

12.8.3 Financials

12.8.4 Key Developments

12.8.5 SWOT Analysis

12.9 Koninklijke Philips N.V.

12.9.1 Overview

12.9.2 Type Overview

12.9.3 Financials

12.9.4 Key Developments

12.9.5 SWOT Analysis

12.10 Siemens Healthcare GmbH

12.10.1 Overview

12.10.2 Type Overview

12.10.3 Financials

12.10.4 Key Developments

12.10.5 SWOT Analysis

12.11 Hitachi Medical Corporation

12.11.1 Overview

12.11.2 Type Overview

12.11.3 Financials

12.11.4 Key Developments

12.11.5 SWOT Analysis

12.12 CANON MEDICAL SYSTEMS CORPORATION

12.12.1 Overview

12.12.2 Type Overview

12.12.3 Financials

12.12.4 Key Developments

12.12.5 SWOT Analysis

12.13 Others

Chapter 13 MRFR Conclusion

13.1 Key Findings

13.1.1 From CEO’s View Point

13.1.2 Unmet Needs of the Market

13.2 Key Companies to Watch

13.3 Prediction of Pulmonary Edema Market

Chapter 14 Appendix

LIST OF TABLES

Table 1 Pulmonary Edema Industry Synopsis, 2020 – 2027

Table 2 Global Pulmonary Edema Market Estimates and Forecast, 2020 – 2027, (USD Million)

Table 3 Global Pulmonary Edema Market by Region, 2020 – 2027, (USD Million)

Table 4 Global Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 5 Global Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 6 Global Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 7 Global Pulmonary Edema Market by End User, 2020 – 2027, (USD Million

Table 8 North America Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 9 North America Pulmonary Edema by Diagnosis, 2020 – 2027, (USD Million)

Table 10 North America Pulmonary Edema by Treatment, 2020 – 2027, (USD Million)

Table 11 North America Pulmonary Edema by End User, 2020 – 2027, (USD Million)

Table 12 U.S. Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 13 U.S. Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 14 U.S. Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 15 U.S. Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

Table 16 Canada Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 17 Canada Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 18 Canada Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 19 Canada Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

Table 20 South America Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 21 South America Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 22 South America Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 23 South America Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

Table 24 Europe Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 25 Europe Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 26 Europe Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 27 Europe Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

Table 28 Western Europe Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 29 Western Europe Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 30 Western Europe Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 31 Western Europe Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

Table 32 Eastern Europe Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 33 Eastern Europe Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 34 Eastern Europe Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 35 Eastern Europe Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

Table 36 Asia Pacific Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 37 Asia Pacific Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 38 Asia Pacific Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 39 Asia Pacific Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

Table 40 The Middle East & Africa Pulmonary Edema Market by Types, 2020 – 2027, (USD Million)

Table 41 The Middle East & Africa Pulmonary Edema Market by Diagnosis, 2020 – 2027, (USD Million)

Table 42 The Middle East & Africa Pulmonary Edema Market by Treatment, 2020 – 2027, (USD Million)

Table 43 The Middle East & Africa Pulmonary Edema Market by End User, 2020 – 2027, (USD Million)

LIST OF FIGURES

Figure 1 Research Process

Figure 2 Segmentation for Global Pulmonary Edema Market

Figure 3 Market Dynamics for Global Pulmonary Edema Market

Figure 4 Global Pulmonary Edema Market Share, by Type 2020

Figure 5 Global Pulmonary Edema Market Share, by Diagnosis 2020

Figure 6 Global Pulmonary Edema Market Share, by Treatment, 2020

Figure 7 Global Pulmonary Edema Market Share, by End User, 2020

Figure 8 Global Pulmonary Edema Market Share, by Region, 2020

Figure 9 North America Pulmonary Edema Market Share, by Country, 2020

Figure 10 Europe Pulmonary Edema Market Share, by Country, 2020

Figure 11 Asia Pacific Pulmonary Edema Market Share, by Country, 2020

Figure 12 The Middle East & Africa Pulmonary Edema Market Share, by Country, 2020

Figure 13 Global Pulmonary Edema Market: Company Share Analysis, 2020 (%)

Figure 14 Pfizer Inc.: Key Financials

Figure 15 Pfizer Inc.: Segmental Revenue

Figure 16 Pfizer Inc.: Geographical Revenue

Figure 17 ARGON MEDICAL: Key Financials

Figure 18 ARGON MEDICAL: Segmental Revenue

Figure 19 ARGON MEDICAL: Geographical Revenue

Figure 20 Edwards Lifesciences Corporation: Key Financials

Figure 21 Edwards Lifesciences Corporation: Segmental Revenue

Figure 22 Edwards Lifesciences Corporation: Geographical Revenue

Figure 23 BD: Key Financials

Figure 24 BD: Segmental Revenue

Figure 25 BD: Geographical Revenue

Figure 26 Alcaliber S.A.: Key Financials

Figure 27 Alcaliber S.A.: Segmental Revenue

Figure 28 Alcaliber S.A.: Geographical Revenue

Figure 29 Lupin Pharmaceuticals, Inc.: Key Financials

Figure 30 Lupin Pharmaceuticals, Inc.: Segmental Revenue

Figure 31 Lupin Pharmaceuticals, Inc.: Geographical Revenue

Figure 32 Vitaltec Corporation: Key Financials

Figure 33 Vitaltec Corporation: Segmental Revenue

Figure 34 Vitaltec Corporation: Geographical Revenue

Figure 35 Medtronic: Key Financials

Figure 36 Medtronic: Segmental Revenue

Figure 37 Medtronic; Geographical Revenue

Figure 38 Koninklijke Philips N.V.: Key Financials

Figure 39 Koninklijke Philips N.V.: Segmental Revenue

Figure 40 Koninklijke Philips N.V.: Geographical Revenue

Figure 41 Siemens Healthcare GmbH: Key Financials

Figure 42 Siemens Healthcare GmbH: Segmental Revenue

Figure 43 Siemens Healthcare GmbH: Geographical Revenue

Figure 44 Hitachi Medical Corporation: Key Financials

Figure 45 Hitachi Medical Corporation: Segmental Revenue

Figure 46 Hitachi Medical Corporation: Geographical Revenue

Figure 47 CANON MEDICAL SYSTEMS CORPORATION: Key Financials

Figure 48 CANON MEDICAL SYSTEMS CORPORATION: Segmental Revenue

Figure 49 CANON MEDICAL SYSTEMS CORPORATION: Geographical Revenue